Mark N Lampert's Net Worth
$0
Who is Mark N Lampert?
Mark N Lampert does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include RIGEL PHARMACEUTICALS INC, Oncothyreon Inc., TARGACEPT INC, Allakos Inc., Rain Therapeutics Inc., ARENA PHARMACEUTICALS INC, IMMUNE DESIGN CORP., Capstone Therapeutics Corp., ChemoCentryx, Inc., DYNAVAX TECHNOLOGIES CORP, REPLIGEN CORP, KENT INTERNATIONAL HOLDINGS INC, NEUROCRINE BIOSCIENCES INC, XOMA Corp, LIGAND PHARMACEUTICALS INC, Xenon Pharmaceuticals Inc., Cullinan Oncology, Inc., Merus N.V., Nivalis Therapeutics, Inc., Repare Therapeutics Inc., PIERIS PHARMACEUTICALS, INC., Verastem, Inc., Syndax Pharmaceuticals Inc, CTI BIOPHARMA CORP, IDEAYA Biosciences, Inc., CYTOKINETICS INC, Kymera Therapeutics, Inc., Calithera Biosciences, Inc., CONCERT PHARMACEUTICALS, INC., PALATIN TECHNOLOGIES INC, MEDICINOVA INC, CytomX Therapeutics, Inc., MoonLake Immunotherapeutics, GLYCOMIMETICS INC, Principia Biopharma Inc., INFINITY PHARMACEUTICALS, INC., Eledon Pharmaceuticals, Inc., Olema Pharmaceuticals, Inc., Regulus Therapeutics Inc., ESSA Pharma Inc., 4D Molecular Therapeutics, Inc., ICAGEN INC, ADOLOR CORP, Third Harmonic Bio, Inc., Regado Biosciences Inc, FIVE PRIME THERAPEUTICS, INC., Structure Therapeutics Inc., ARRAY BIOPHARMA INC, ARQULE INC, enGene Holdings Inc., Celera CORP, FACET BIOTECH CORP, AVIGEN INC \DE, POINT Biopharma Global Inc., SUPERGEN INC, COMBINATORX, INC, and NEUROBIOLOGICAL TECHNOLOGIES INC /CA/.
SEC CIK
Mark N Lampert's CIK is 0001233840
Past Insider Trading and Trends
2016 was Mark N Lampert's most active year for acquiring shares with 3 total transactions. Mark N Lampert's most active month to acquire stocks was the month of May. 2016 saw Mark N Lampert paying a total of $8,842,400.00 for 11,053 shares, this is the most they've acquired in one year.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Allakos Inc. (ALLK) Snapshot price: $0.648
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Rain Oncology Inc. (RAIN) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -8.58M |
—
|
—
|
0
|
Jan 25 - Jan 26
| |||
Form 4
| +47.80% | 1.71M |
$5.83 | $9,971,387.14 | 5.29M |
Nov 8
| |||
Form 4
| +20.43% | 557.73K |
$12.00 | $6,692,637.85 | 3.29M |
Jan 6 - Jan 7
| |||
Form 4
| +0.41% | 11.03K |
$13.94 | $153,828.71 | 2.73M |
Sep 21
| |||
Form 4
| +16.86% | 392.27K |
$16.49 | $6,468,515.81 | 2.72M |
Sep 13
| |||
Form 4
| +33.73% | 587K |
$15.47 | $9,078,692.10 | 2.33M |
Jul 1 - Jul 6
| |||
Form 4
| +7.63% | 123.35K |
$15.94 | $1,966,334.17 | 1.74M |
May 21 - May 24
| |||
Form 4
| +14.80% | 208.47K |
$16.59 | $3,457,720.14 | 1.62M |
May 18 - May 19
| |||
Form 4
| +4.30% | 58K |
$14.26 | $827,167.00 | 1.41M |
May 13
| |||
Form 4/A
| +522.18% | 1.13M |
$16.86 | $19,103,379.78 | 1.35M |
Apr 23 - Apr 26
| |||
Form 4
|
∞
| 4.93M |
$16.86 |
—
| 4.93M |
Apr 23 - Apr 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
IMMUNE DESIGN CORP. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -15.77% | -902.00K |
$1.83 | -$1,653,907.20 | 4.82M |
Dec 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Cascadian Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -41.40% | -4.00M |
—
|
—
| 5.66M |
Feb 5
| |||
Form 4
| +4.08% | 378.44K |
$1.82 | $688,678.86 | 9.66M |
Dec 15 - Dec 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -7.41% | -554.24K |
$3.24 | -$1,795,731.12 | 6.92M |
Jul 16
| |||
Form 4
| +1.76% | 129K |
$1.78 | $229,620.00 | 7.48M |
Nov 1
| |||
Form 4
| +3.64% | 258.36K |
$1.65 | $426,166.47 | 7.35M |
Aug 8
| |||
Form 4
| +5.01% | 338.09K |
$1.76 | $589,602.29 | 7.09M |
Jul 31 - Aug 1
| |||
Form 4
| +1.09% | 214.47K |
$1.79 | $387,225.99 | 19.95M |
Jun 5 - Jun 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Capstone Therapeutics Corp. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -65.68% | -4.34M |
$0.06 | -$260,495.16 | 2.27M |
Jul 14
| |||
Form 4
| -13.37% | -616.56K |
$0.30 | -$184,968.90 | 3.99M |
Jul 1
| |||
Form 4
| +4.53% | 312.9K |
$0.26 | $81,041.10 | 7.23M |
Sep 6
| |||
Form 4
| +0.44% | 78.9K |
$0.26 | $20,514.00 | 18.2M |
Aug 18 - Aug 22
| |||
Form 4
| +8.71% | 954.25K |
$0.25 | $238,562.50 | 11.91M |
Jul 28 - Jul 29
| |||
Form 4
| +0.37% | 18.4K |
$0.25 | $4,600.00 | 5.05M |
Jul 26
| |||
Form 4
| +5.28% | 252.6K |
$0.25 | $63,099.48 | 5.03M |
Jul 20
| |||
Form 4
| +4.70% | 358.6K |
$0.25 | $89,344.99 | 7.99M |
Jul 14 - Jul 18
| |||
Form 4
| +0.28% | 9K |
$0.25 | $2,250.00 | 3.19M |
Jul 11
| |||
Form 4
| +0.09% | 4.7K |
$0.25 | $1,171.72 | 5.24M |
Jun 30
| |||
Form 4
| +1.95% | 100.05K |
$0.25 | $24,990.49 | 5.24M |
Jun 27 - Jun 29
| |||
| No matching records found | |||||||||